Biodesix Inc (NASDAQ: BDSX) on Tuesday, plunged -2.00% from the previous trading day, before settling in for the closing price of $0.50. Within the past 52 weeks, BDSX’s price has moved between $0.48 and $2.04.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 29.81% annually for the last half of the decade. The company achieved an average annual earnings per share of 37.37%. With a float of $73.90 million, this company’s outstanding shares have now reached $145.49 million.
In an organization with 273 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 78.17%, operating margin of -48.18%, and the pretax margin is -60.19%.
Biodesix Inc (BDSX) Insider Updates
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of Biodesix Inc is 49.38%, while institutional ownership is 40.20%. The most recent insider transaction that took place on Feb 11 ’25, was worth 3,355. In this transaction Chief Accounting Officer of this company sold 3,630 shares at a rate of $0.92, taking the stock ownership to the 17,623 shares. Before that another transaction happened on Feb 11 ’25, when Company’s Chief Development Officer sold 16,748 for $0.92, making the entire transaction worth $15,479. This insider now owns 156,008 shares in total.
Biodesix Inc (BDSX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 37.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 38.97% during the next five years compared to 69.26% growth over the previous five years of trading.
Biodesix Inc (NASDAQ: BDSX) Trading Performance Indicators
Biodesix Inc (BDSX) is currently performing well based on its current performance indicators. A quick ratio of 2.69 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.14 in one year’s time.
Technical Analysis of Biodesix Inc (BDSX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.39 million. That was inferior than the volume of 0.43 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 11.63%. Additionally, its Average True Range was 0.07.
During the past 100 days, Biodesix Inc’s (BDSX) raw stochastic average was set at 0.59%, which indicates a significant decrease from 3.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 89.23% in the past 14 days, which was higher than the 81.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7467, while its 200-day Moving Average is $1.3278. However, in the short run, Biodesix Inc’s stock first resistance to watch stands at $0.5107. Second resistance stands at $0.5315. The third major resistance level sits at $0.5430. If the price goes on to break the first support level at $0.4784, it is likely to go to the next support level at $0.4669. Assuming the price breaks the second support level, the third support level stands at $0.4461.
Biodesix Inc (NASDAQ: BDSX) Key Stats
Market capitalization of the company is 71.53 million based on 145,978K outstanding shares. Right now, sales total 71,320 K and income totals -42,930 K. The company made 20,430 K in profit during its latest quarter, and -8,250 K in sales during its previous quarter.
